Literature DB >> 25472864

140 mmol/L of sodium versus 77 mmol/L of sodium in maintenance intravenous fluid therapy for children in hospital (PIMS): a randomised controlled double-blind trial.

Sarah McNab1, Trevor Duke2, Mike South3, Franz E Babl4, Katherine J Lee5, Sarah J Arnup6, Simon Young7, Hannah Turner6, Andrew Davidson8.   

Abstract

BACKGROUND: Use of hypotonic intravenous fluid to maintain hydration in children in hospital has been associated with hyponatraemia, leading to neurological morbidity and mortality. We aimed to assess whether use of fluid solutions with a higher sodium concentration reduced the risk of hyponatraemia compared with use of hypotonic solutions.
METHODS: We did a randomised controlled double-blind trial of children admitted to The Royal Children's Hospital (Melbourne, VIC, Australia) who needed intravenous maintenance hydration for 6 h or longer. With an online randomisation system that used unequal block sizes, we randomly assigned patients (1:1) to receive either isotonic intravenous fluid containing 140 mmol/L of sodium (Na140) or hypotonic fluid containing 77 mmol/L of sodium (Na77) for 72 h or until their intravenous fluid rate decreased to lower than 50% of the standard maintenance rate. We stratified assignment by baseline sodium concentrations. Study investigators, treating clinicians, nurses, and patients were masked to treatment assignment. The primary outcome was occurrence of hyponatraemia (serum sodium concentration <135 mmol/L with a decrease of at least 3 mmol/L from baseline) during the treatment period, analysed by intention to treat. The trial was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN1260900924257.
FINDINGS: Between Feb 2, 2010, and Jan 29, 2013, we randomly assigned 690 patients. Of these patients, primary outcome data were available for 319 who received Na140 and 322 who received Na77. Fewer patients given Na140 than those given Na77 developed hyponatraemia (12 patients [4%] vs 35 [11%]; odds ratio [OR] 0·31, 95% CI 0·16-0·61; p=0·001). No clinically apparent cerebral oedema occurred in either group. Eight patients in the Na140 group (two potentially related to intravenous fluid) and four in the Na77 group (none related to intravenous fluid) developed serious adverse events during the treatment period. One patient in the Na140 had seizures during the treatment period compared with seven who received Na77.
INTERPRETATION: Use of isotonic intravenous fluid with a sodium concentration of 140 mmol/L had a lower risk of hyponatraemia without an increase in adverse effects than did fluid containing 77 mmol/L of sodium. An isotonic fluid should be used as intravenous fluid for maintenance hydration in children. FUNDING: National Health and Medical Research Council, Murdoch Childrens Research Institute, The Royal Children's Hospital, and the Australian and New Zealand College of Anaesthetists.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25472864     DOI: 10.1016/S0140-6736(14)61459-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  35 in total

1.  The impact of intravenous isotonic and hypotonic maintenance fluid on the risk of delirium in adult postoperative patients: retrospective before-after observational study.

Authors:  Masaharu Nagae; Moritoki Egi; Nana Furushima; Masako Okada; Shohei Makino; Satoshi Mizobuchi
Journal:  J Anesth       Date:  2019-02-26       Impact factor: 2.078

2.  Hyponatraemia: Isotonic fluids prevent hospital-acquired hyponatraemia.

Authors:  Michael L Moritz; Juan C Ayus
Journal:  Nat Rev Nephrol       Date:  2015-01-20       Impact factor: 28.314

Review 3.  Teaching Pediatric Life Support in Limited-Resource Settings: Contextualized Management Guidelines.

Authors:  Mark E Ralston; Allan de Caen
Journal:  J Pediatr Intensive Care       Date:  2016-06-29

4.  Perioperative fluid management and postoperative hyponatremia in children.

Authors:  Gia J Oh; Scott M Sutherland
Journal:  Pediatr Nephrol       Date:  2015-03-18       Impact factor: 3.714

5.  Washing in hypotonic saline reduces the fraction of irreversibly-damaged cells in stored blood: a proof-of-concept study.

Authors:  Hui Xia; Grishma Khanal; Briony C Strachan; Eszter Vörös; Nathaniel Z Piety; Sean C Gifford; Sergey S Shevkoplyas
Journal:  Blood Transfus       Date:  2017-05-11       Impact factor: 3.443

6.  Comparison of the incidences of hyponatremia in adult postoperative critically ill patients receiving intravenous maintenance fluids with 140 mmol/L or 35 mmol/L of sodium: retrospective before/after observational study.

Authors:  Masako Okada; Moritoki Egi; Yuri Yokota; Naotaka Shirakawa; Daichi Fujimoto; Shinya Taguchi; Nana Furushima; Satoshi Mizobuchi
Journal:  J Anesth       Date:  2017-04-28       Impact factor: 2.078

7.  Intravenous Fluid Prescription Practices in Critically Ill Children: A Shift in Focus from Natremia to Chloremia?

Authors:  Adrian F Bulfon; Hakem L Alomani; Natalie Anton; Brooke T Comrie; Bram Rochwerg; Sorina A Stef; Lehana Thabane; Thuva Vanniyasingam; Karen Choong
Journal:  J Pediatr Intensive Care       Date:  2019-06-19

8.  Choice of maintenance intravenous fluids among paediatric residents in Canada.

Authors:  Laura M Kinlin; Andrew J Helmers; Jeremy N Friedman; Carolyn E Beck
Journal:  Paediatr Child Health       Date:  2019-09-19       Impact factor: 2.253

9.  Use of Hypotonic Maintenance Intravenous Fluids and Hospital-Acquired Hyponatremia Remain Common in Children Admitted to a General Pediatric Ward.

Authors:  Shikha Shukla; Srikanta Basu; Michael L Moritz
Journal:  Front Pediatr       Date:  2016-08-25       Impact factor: 3.418

10.  Hypotonic fluid reduce serum sodium compared to isotonic fluids during anesthesia induction in pediatric patients undergoing maxillofacial surgery-type of infusion affects blood electrolytes and glucose: an observational study.

Authors:  Kentaro Ouchi; Kazuna Sugiyama
Journal:  BMC Pediatr       Date:  2016-07-27       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.